Juan Miguel Mosquera, M.D., M.Sc.

Juan Mosquera

Dr. Juan Miguel Mosquera is Assistant Professor of Pathology and Laboratory Medicine at the Weill Cornell Medical College and an Assistant Attending Pathologist at the New York-Presbyterian Hospital (Cornell Campus). He is board certified by the American Board of Pathology in Anatomic and Clinical Pathology, and by the Royal College of Physicians and Surgeons of Canada in Anatomic Pathology.

Dr. Mosquera has subspecialty expertise in Genitourinary Pathology. His research interests include genomics of prostate cancer, development of tissue-based biomarkers and soft tissue pathology.

A graduate of Universidad Nacional de Colombia, Dr. Mosquera completed his residency and Surgical Pathology Fellowship at Rush University Medical Center in Chicago, IL, followed by Fellowships in Genitourinary Pathology and Translational Research at Brigham and Women’s Hospital in Boston, MA, under the mentorship of Dr. Mark Rubin.

Dr. Mosquera has co-authored more than 40 peer-reviewed publications and serves as Section Editor in Precision Medicine for Archives of Pathology & Laboratory Medicine. He is lead pathologist in validation studies of the Early Detection Research Network (EDRN), and lead pathologist at the Institute for Precision Medicine of WCMC-NYP.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • United Health Care
  • VNSNY CHOICE Medicare [Medicare]

Publications

1. Shaw JA, Udukang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J of Pathol 2002; 198: 450-457

 

2. Restelli M, Grinstein S, Gattuso P, Preciado MV, Brunzini MA, Zarate J, Mosquera JM, Gould VE. Immunolocalization of the Epstein-Barr nuclear antigen-1 in conjunctival squamous carcinomas and dysplasias. Hum Pathol 2005; 36(4): 325-329

 

3. Gould VE, Mosquera JM, Leykauf K, Gattuso P, Duerst M, Alonso A. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries. Hum Pathol 2005; 36(5): 536-545.

 

4. Cobleigh MA, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Tabesh B, Mosquera JM, Walker MG, Shak S. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive lymph nodes: High throughput RT-PCR assay of paraffin-embedded tumor tissues.  Clin Cancer Res 2005; 11: 8623-8631.

 

5. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Tchinda J, Tomlins S, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson ML, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA. TMPRSS2:ERG fusion associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66 (17): 8337-8341.

 

6. Setlur, SR; Royce, TE; Sboner, A; Mosquera, JM; Demichelis, F; Hofer, MD; Mertz, KD; Gerstein, M; Rubin, MA. Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer. Cancer Res 2007; 67: 10296 - 10303.

 

7. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur S , Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci L, Kantoff P, Andersson SO, Chinnaiyan A, Johansson JE, Rubin MA. TMPRSS2:ERG Gene Fusion Associated with Lethal Prostate Cancer in a Watchful Waiting Cohort. Oncogene 2007 26 (31): 4596-9

 

8. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG Fusion Prostate Cancer: an early molecular event associated with invasion. Am J Surg Path 2007; 31 (6): 882-8.

 

9. Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA. Morphological features of TMPRSS2-ERG Gene Fusion Prostate Cancer. J Pathol 2007; 212 (1): 91-101

 

10. Mosquera JM, Perner S, Genega EM, Sanda MG, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 3380-3385

 

11. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer. Clin Cancer Res 2009; 15: 5794-802

 

12. Choueiri TK, Mosquera JM, Hirsch MS. A Case of Adult Metastatic Xp11 Translocation Renal Cell Carcinoma Treated Successfully With Sunitinib. Clin Genitourinary Cancer 2009; 7 (3): E93-94

 

13. Mosquera JM, Mehra R, Regan M, Genega EM, Bueti G, Gaston S, Tomlins SA, Shah RB, Wei J, Kearney M, Perner S, Johnson LA, Tang JM, Chinnaiyan AM, Sanda MG, Rubin MA. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer Among Men Undergoing Prostate Biopsy in the United States. Clin Cancer Res 2009; 15: 4706 - 4711

 

14. Mosquera JM, Fletcher CDM. Expanding the spectrum of malignant progression in solitary fibrous tumor (SFT): a study of 8 cases with a discrete anaplastic component - is this dedifferentiated SFT?  Am J Surg Path 2009; 33: 1314-1321

 

15. Kenney PA, Wszolek MF, Rieger-Christ KM, Silva Neto B, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC. Novel ZEB1 Expression in Bladder Tumorigenesis. BJU Int 2011; 107 (4): 656-63

 

16. Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA, Hirsch MS. Validation of a TFE3 break-apart FISH assay in Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol 2011; 20 (3): 129-137

 

17. Rickman DS, Soong TD, Moss B, Mosquera JM, Terry S, MacDonald TY, Bunting K, Demichelis F, Melnick AM, Elemento O, Rubin MA. Oncogene-Mediated Alterations in Chromatin Conformation. Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9083-8.

 

18. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio R, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet, 2012. 44(6): 685-9.

 

19. Beltran H, Tagawa ST, Park K, MacDonald TY, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM. Challenges in Recognizing Treatment Related Neuroendocrine Prostate Cancer. J Clin Oncol, 2012. 30 (36): e386-9

 

20. Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol 2012, S1078-1439(12)00237-2.

 

21. Beltran H, Yelensky R, Frampton G, Park K, Downing S, MacDonald TY, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA. Targeted Next Generation Sequencing of Advanced Prostate Cancer Identifies New Therapeutic Targets and Disease Heterogeneity. Eur Urol 2012. S0302-2838(12)01006-8

 

22. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro R, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer M, Roychowdhury S, Siddiqui J, Pienta K, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze S, Antonescu CR, Chinnaiyan AM. Identification of Recurrent NAB2-STAT6 Gene Fusions in Solitary Fibrous Tumor by Integrative Sequencing. Nature Genetics 2013, Feb;45(2):180-5.

 

23. Mosquera JM*, Beltran H*, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013, Jan;15(1):1-10.

24. Antonescu CR, Romeo S, Zhang L, Nafa K, Hornick JL, Petur Nielsen G, Mino-Kenudson M, Huang HY, Mosquera JM, Dei Tos PA, Fletcher CDM. Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT Negative Phenotype – a Diagnostic Pitfall. Morphologic and Molecular Characterization of 8 Cases Occurring either de-novo or after Imatinib Therapy. Am J Surg Pathol, 2013, Mar; 37(3):385-92.

25. Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen LC, Sung YS, Wexler LH, LaQuaglia MP, Edelman M, Sreekantaiah, Rubin MA, Antonescu CR. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom Cancer 2013, Epub ahed of print.

 

26. Schaefer G*, Mosquera JM*, Ramoner R, Park K, Romanel A, Steiner E, Horninger W, Bektic J, Ladurner-Rennau M, Rubin MA, Demichelis F, Klocker H. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer P D 2013, Epub ahead of print.

 

27. Bhalla R, Kunju LP, Tomlins SA,  Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Mosquera JM, Pestano G, Rubin MA, Chinnaiyan A, Palanisamy N. Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol 2013, Epub ahead of print.

 

28. Martz J, Jain S, Vahdat LT, Qi L, Mosquera JM, Antonescu CR, Popa EC. High-grade KIT- negative sarcoma of the small bowel in a patient with CML on long-term tyrosine kinase inhibitors: case report and review of the literature. J Clin Oncol, 2013, 31(11):e181-5.

 

29. Lin PC, Giannopoulou E, Park K, Mosquera JM, Sboner A, Beltran H, Rubin MA, Elemento O. Epigenomics alterations in indolent and aggressive prostate cancer. Neoplasia 2013, Apr; 15(4):373-83.

 

30. Lin PC, Chui, YL, Banerjee S, Alves P, Giannopoulou E, Park K, Mosquera JM, Tewari A, Gerstein MB, Beltran H, Melnick A, Elemento O, Demichelis F, Rubin MA. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013, Feb; 73(3): 1232-44.

 

31. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K,  Kitabayashi N, MacDonald TY, Van Allen E, Kryukov GV, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. Punctuated Evolution of Prostate Cancer Genomes. Cell 2013, Apr 25;153(3):666-77.

 

32. Antonescu CR, Zhang L, Shao SY, Mosquera JM, Weinreb I, Katabi N, Fletcher CDM. Frequent PLAG1 gene rearrangements in skin and soft tissue myoepithelioma with ductal differentiation. Genes Chromosom Cancer 2013Jul;52(7):675-82

 

33. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen LC, Chen HW, Pathan N, Krausz T, Dickson BC,  Weinreb I, Rubin MA, Hameed M, Fletcher CDM. Novel YAP1-TFE3 Fusion Defines a Distinct Subset of Epithelioid Hemangioendothelioma. Genes Chromosom Cancer 2013, Aug;52(8):775-84.

34. Park K, Chiu Y-L, Rubin MA, Demichelis F*, Mosquera JM*. ERG/TFF3/HMWCK triple immunostain:  A novel tissue-based biomarker in prostate cancer with potential clinical application. Human Pathol 2013, Oct;44(10):2282-92.

 

35. The Cancer Genome Atlas Research Network; Analysis working group: Baylor College of Medicine, Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA; BC Cancer Agency, Gordon Robertson A, Chu A; Broad Institute, Beroukhim R, Cibulskis K; Brigham & Women’s Hospital, Signoretti S; Brown University, Vandin Hsin-Ta Wu F, Raphael BJ; The University of Texas MD Anderson Cancer Center, Verhaak RG, Tamboli P, Torres-Garcia W, Akbani R, Weinstein JN; Memorial Sloan-Kettering Cancer Center, Reuter V, Hsieh JJ, Rose Brannon A, Ari Hakimi A, Jacobsen A, Ciriello G, Reva B; National Cancer Institute, Ricketts CJ, Marston Linehan W; University of California Santa Cruz, Stuart JM; University of North Carolina, Chapel Hill, Kimryn Rathmell W; University of Southern California, Shen H, Laird PW; Genome sequencing centres: Baylor College of Medicine, Muzny D, Davis C, Morgan M, Xi L, Chang K, Kakkar N, Treviño LR, Benton S, Reid JG, Morton D, Doddapaneni H, Han Y, Lewis L, Dinh H, Kovar C, Zhu Y, Santibanez J, Wang M, Hale W, Kalra D, Creighton CJ, Wheeler DA, Gibbs RA; Broad Institute, Getz G, Cibulskis K, Lawrence MS, Sougnez C, Carter SL, Sivachenko A, Lichtenstein L, Stewart C, Voet D, Fisher S, Gabriel SB, Lander E; Genome characterization centres: Broad Institute, Beroukhim R, Schumacher SE, Tabak B, Saksena G, Onofrio RC, Carter SL, Cherniack AD, Gentry J, Ardlie K, Sougnez C, Getz G, Gabriel SB, Meyerson M; BC Cancer Agency, Gordon Robertson A, Chu A, Chun HJ, Mungall AJ, Sipahimalani P, Stoll D, Ally A, Balasundaram M, Butterfield YS, Carlsen R, Carter C, Chuah E, Coope RJ, Dhalla N, Gorski S, Guin R, Hirst C, Hirst M, Holt RA, Lebovitz C, Lee D, Li HI, Mayo M, Moore RA, Pleasance E, Plettner P, Schein JE, Shafiei A, Slobodan JR, Tam A, Thiessen N, Varhol RJ, Wye N, Zhao Y, Birol I, Jones SJ, Marra MA; University of North Carolina, Chapel Hill, Auman JT, Tan D, Jones CD, Hoadley KA, Mieczkowski PA, Mose LE, Jefferys SR, Topal MD, Liquori C, Turman YJ, Shi Y, Waring S, Buda E, Walsh J, Wu J, Bodenheimer T, Hoyle AP, Simons JV, Soloway MG, Balu S, Parker JS, Neil Hayes D, Perou CM; Harvard Medical School, Kucherlapati R, Park P; University of Southern California & Johns Hopkins University, Shen H, Triche Jr T, Weisenberger DJ, Lai PH, Bootwalla MS, Maglinte DT, Mahurkar S, Berman BP, Van Den Berg DJ, Cope L, Baylin SB, Laird PW; Genome data analysis: Baylor College of Medicine, Creighton CJ, Wheeler DA; Broad Institute, Getz G, Noble MS, Dicara D, Zhang H, Cho J, Heiman DI, Gehlenborg N, Voet D, Mallard W, Lin P, Frazer S, Stojanov P, Liu Y, Zhou L, Kim J, Lawrence MS, Chin L; Brown University, Vandin F, Wu HT, Raphael BJ; Buck Institute for Research on Aging, Benz C, Yau C; Institute for Systems Biology, Reynolds SM, Shmulevich I; The University of Texas MD Anderson Cancer Center, Verhaak RG, Torres-Garcia W, Vegesna R, Kim H, Zhang W, Cogdell D, Jonasch E, Ding Z, Lu Y, Akbani R, Zhang N, Unruh AK, Casasent TD, Wakefield C, Tsavachidou D, Chin L, Mills GB, Weinstein JN; Memorial Sloan-Kettering Cancer Center, Jacobsen A, Rose Brannon A, Ciriello G, Schultz N, Ari Hakimi A, Reva B, Antipin Y, Gao J, Cerami E, Gross B, Arman Aksoy B, Sinha R, Weinhold N, Onur Sumer S, Taylor BS, Shen R, Ostrovnaya I, Hsieh JJ, Berger MF, Ladanyi M, Sander C; Oregon Health & Science University, Fei SS, Stout A, Spellman PT; Stanford University, Rubin DL, Liu TT; University of California Santa Cruz, Stuart JM, Ng S, Paull EO, Carlin D, Goldstein T, Waltman P, Ellrott K, Zhu J, Haussler D; University of Houston, Gunaratne PH, Xiao W; Biospecimen core resource: International Genomics Consortium, Shelton C, Gardner J, Penny R, Sherman M, Mallery D, Morris S, Paulauskis J, Burnett K, Shelton T; Tissue source sites: Brigham & Women’s Hospital, Signoretti S; Dana-Farber Cancer Institute, Kaelin WG, Choueiri T; Georgetown University, Atkins MB; International Genomics Consortium, Penny R, Burnett K, Mallery D, Curley E; Memorial Sloan-Kettering Cancer Center, Tickoo S, Reuter V; University of North Carolina at Chapel Hill, Kimryn Rathmell W, Thorne L, Boice L, Huang M, Fisher JC; National Cancer Institute, Marston Linehan W, Vocke CD, Peterson J, Worrell R, Merino MJ, Schmidt LS; The University of Texas MD Anderson Cancer Center, Tamboli P, Czerniak BA, Aldape KD, Wood CG; Fox Chase Cancer Center, Boyd J, Weaver J; Helen F Graham Cancer Center at Christiana Care, Iacocca MV, Petrelli N, Witkin G, Brown J, Czerwinski C, Huelsenbeck-Dill L, Rabeno B; Penrose-St. Francis Health Services, Myers J, Morrison C, Bergsten J, Eckman J, Harr J, Smith C, Tucker K, Anne Zach L; Roswell Park Cancer Institute, Bshara W, Gaudioso C, Morrison C; University of Pittsburgh, Dhir R, Maranchie J, Nelson J, Parwani A; Cureline, Potapova O; St. Petersburg City Clinical Oncology Dispensary, Fedosenko K; Mayo Clinic, Cheville JC, Houston Thompson R; Disease working group: Brigham & Women’s Hospital, Signoretti S; Dana-Farber Cancer Institute, Kaelin WG; Georgetown University, Atkins MB; Memorial Sloan-Kettering Cancer Center, Tickoo S, Reuter V; National Cancer Institute, Marston Linehan W, Vocke CD, Peterson J, Merino MJ, Schmidt LS; The University of Texas MD Anderson Cancer Center, Tamboli P; Weill Cornell Medical College, Mosquera JM, Rubin MA; Massachusetts General Hospital, Blute ML; University of North Carolina, Chapel Hill, Kimryn Rathmell W; Data coordination centre, Pihl T, Jensen M, Sfeir R, Kahn A, Chu A, Kothiyal P, Snyder E, Pontius J, Ayala B, Backus M, Walton J, Baboud J, Berton D, Nicholls M, Srinivasan D, Raman R, Girshik S, Kigonya P, Alonso S, Sanbhadti R, Barletta S, Pot D; Project team: National Cancer Institute, Sheth M, Demchok JA, Davidsen T, Wang Z, Yang L, Tarnuzzer RW, Zhang J, Eley G, Ferguson ML, Mills Shaw KR; National Human Genome Research Institute, Guyer MS, Ozenberger BA, Sofia HJ. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, Jul 4;499(7456):43-9].

36. Mosquera JM, Sboner A, Zhang L, Chen LC, Sung YS, Chen HW, Agaram NP, Briskin D, Basha B, Singer S, Rubin MA, Tuschl T, Antonescu CR. Novel miR143-NOTCH Fusions in Benign and Malignant Glomus Tumors. Genes Chromosom Cancer 2013. Nov;52(11):1075-87. doi: 10.1002/gcc.22102. Epub 2013 Sep 2. 

PMID:
 
23999936

37. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Sun J, White J, Sanford EM, An P, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahoue A, Schnall-Levin M, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R. Validation and clinical application of a cancer genomic profiling test using next-generation sequencing. Nature Biotechnol 2013, Nov; 31(11):1023-31.

38. Ginter PS, Mosquera JM, MacDonald TY, D’Alfonso TM, Rubin MA, Shin SJ. Diagnostic utility of MYC amplification and Anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas and primary angiosarcomas of other sites. Human Pathol 2013. Nov 12. pii: S0046-8177(13)00475-9. doi: 10.1016/j.humpath.2013.11.002. [Epub ahead of print].

39. Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Palma PD, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev 2014. Accepted

40. Blattner M, Lee D, O´Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S,  Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS,  Known YC, Andren O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 2014. Accepted

41. Epstein JI, Amin MB, Beltran H, Lotan T, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. Proposed Morphologic Classification of Prostate Cancer with Neuroendocrine Differentiation. Am J Surg Path 2014. Jun;38(6):756-67

42. Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk M, Robinson BD, Beltran H, Rubin MA, Mosquera JM. Prostate Cancer with Paneth Cell-Like Neuroendocrine Differentiation has Recognizable Histomorphology and Harbors AURKA Gene Amplification. Human Pathol 2014. Accepted

 

Honors and Awards

Stowell-Orbison Award Honorable Mention (USCAP) - 2004

Excellence in Urological Pathology Resident Research Award (Int’l Soc Urological Pathology) - 2007

Stowell-Orbison Award Certificate of Merit (USCAP) - 2008